ArticleScience translational medicine2019
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05849610 (An Open Label, Multicenter, Phase 2, Pilot Study, Evaluating Early Treatment With Bispecific T-cell Redirectors), which is not on this map. Cited by 249 papers, 7 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
249citing papers in PubMed, 7 pooled it
15.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT05849610 phase2active not recruitingnot on this mapstarted 2023, after this paper: background citation
An Open Label, Multicenter, Phase 2, Pilot Study, Evaluating Early Treatment With Bispecific T-cell Redirectors (Teclistamab and Talquetamab) in the Frontline Therapy of Newly Diagnosed High-risk Multiple Myeloma
Who cites it
249 citing papers in PubMed, 7 syntheses or guidelines pooled it, 374 citations in OpenAlex.
- Subsequent CAR-T and engineered antibody for relapsed/refractory multiple myeloma following BCMA-targeted treatment: a systematic review and meta-analysis.Blood cancer journal · 2026Pooled it
- Infection risk associated with talquetamab in relapsed/refractory multiple myeloma: a systematic review with meta-analysis of talquetamab monotherapy and descriptive analysis of combination therapy.Frontiers in immunology · 2026Pooled it
- Efficacy and safety of BCMA- or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies.Frontiers in immunology · 2026Pooled it
- Efficacy and safety of CD38-directed CAR-T cell therapy for multiple myeloma: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- A Systematic Review and Meta-analysis on the Safety and Efficacy of CAR T Cell Therapy Targeting GPRC5D in Patients with Multiple Myeloma: A New Insight in Cancer Immunotherapy.Anti-cancer agents in medicinal chemistry · 2025Pooled it
- Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.Transplantation and cellular therapy · 2024Guideline
- Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma.Frontiers in immunology · 2024Pooled it
- Trial
- Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells.Blood cancer journal · 2024Trial
- Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.Clinical pharmacology and therapeutics · 2026Article
- Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myeloma.HemaSphere · 2026Article
- Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma.Clinical pharmacology and therapeutics · 2026Article
- Target-Specific Dermatological Adverse Event Reporting With T-Cell-Engaging Bispecific Antibodies: A Pharmacovigilance Analysis of FAERS and Canada Vigilance, 2016-2026.Cancer medicine · 2026Article
- Review
- Multidisciplinary approach to managing GPRC5D-related adverse events in relapsed or refractory multiple myeloma patients.Annals of hematology · 2026Review
- Navigating the Therapeutic Landscape of Multiple Myeloma: Immunotherapy, Microenvironment, and Resistance.Biomedicines · 2026Review
- Dermatologic Adverse Events Associated with T-Cell Engager Therapy.American journal of clinical dermatology · 2026Review
- Review
- GPCRs in CAR-T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
189 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 5 institutions in 3 countries.
Eric L SmithCellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-0296-7587
Kim HarringtonJuno Therapeutics, A Celgene Company, Seattle, WA 98109, USA.
Mette StaehrCellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0001-8680-4373
Reed MasakayanCellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0003-3591-8869
Jon JonesJuno Therapeutics, A Celgene Company, Seattle, WA 98109, USA.ORCID 0000-0003-3870-3337
Thomas J LongJuno Therapeutics, A Celgene Company, Seattle, WA 98109, USA.
Khong Y NgSloan Kettering Institute, New York, NY 10065, USA.ORCID 0000-0003-4373-850X
Majid GhoddusiJuno Therapeutics, A Celgene Company, Seattle, WA 98109, USA.ORCID 0000-0001-7552-2418
Terence J PurdonCellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Xiuyan WangCell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Trevor DoJuno Therapeutics, A Celgene Company, Seattle, WA 98109, USA.
Minh Thu PhamJuno Therapeutics, A Celgene Company, Seattle, WA 98109, USA.
Jessica M BrownJuno Therapeutics, A Celgene Company, Seattle, WA 98109, USA.ORCID 0000-0001-9031-9987
Carlos Fernandez De LarreaCellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Eric OlsonJuno Therapeutics, A Celgene Company, Seattle, WA 98109, USA.
Elizabeth PegueroSloan Kettering Institute, New York, NY 10065, USA.ORCID 0000-0003-2387-3595
Pei WangEureka Therapeutics, Emeryville, CA 94608, USA.
Hong LiuEureka Therapeutics, Emeryville, CA 94608, USA.
Yiyang XuEureka Therapeutics, Emeryville, CA 94608, USA.
Sarah C Garrett-ThomsonDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USA.ORCID 0000-0002-3073-1571
Steven C AlmoDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Hans-Guido WendelSloan Kettering Institute, New York, NY 10065, USA.ORCID 0000-0001-7166-4670
Isabelle RiviereCell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Cheng LiuEureka Therapeutics, Emeryville, CA 94608, USA.
Blythe SatherJuno Therapeutics, A Celgene Company, Seattle, WA 98109, USA.ORCID 0000-0001-6582-0243
Renier J BrentjensCellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. brentjer@mskcc.org.ORCID 0000-0002-3364-5388
Juno Therapeutics (Germany) · DEMemorial Sloan Kettering Cancer Center · USEureka Therapeutics (United States) · USKettering University · USAlbert Einstein College of Medicine · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MWORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI THOMAS E ROHAN · 1985 to 2026
$111.2MTUMORICIDAL FUNCTIONS OF T LYMPHOCYTES IN PSMA TUMORSP01CA059350 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI O'REILLY, RICHARD JOHN · 1992 to 2012
$21.4MPersonalized Immunotherapy of Patients with Ovarian CancerP01CA190174 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SABBATINI, PAUL J, SPRIGGS, DAVID R · 2015 to 2019
$10.5MMSKCC Pilot Center for Precision Disease ModelingU54OD020355 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI LOWE, SCOTT W., SOLIT, DAVID B. · 2015 to 2019
$9.9MAdoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cellsR01CA138738 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BRENTJENS, RENIER JOSEPH · 2009 to 2013
$3.9MNovel Strategies for Precision T-cell TherapiesR01CA198095 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI ALMO, STEVEN C. · 2016 to 2020
$2.8MTechnologies for Mapping the Extracellular InteractomeR01HG008325 · NHGRI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI ALMO, STEVEN C. · 2015 to 2017
$1.9MNCI NIH HHS P01 CA059350NCI NIH HHS P01 CA190174NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA013330NCI NIH HHS R01 CA138738NCI NIH HHS R01 CA198095NHGRI NIH HHS R01 HG008325NIH HHS U54 OD020355
Abstract
Early clinical results of chimeric antigen receptor (CAR) T cell therapy targeting B cell maturation antigen (BCMA) for multiple myeloma (MM) appear promising, but relapses associated with residual low-to-negative BCMA-expressing MM cells have been reported, necessitating identification of additional targets. The orphan G protein-coupled receptor, class C group 5 member D (
Indexed as
AnimalsAntibody SpecificityB-Cell Maturation AntigenCell Line, TumorGene ExpressionHumansImmunotherapy, AdoptiveMiceMice, Inbred NODMice, SCIDMultiple MyelomaReceptors, Chimeric AntigenReceptors, G-Protein-CoupledRNA, MessengerSingle-Chain AntibodiesTranslational Research, BiomedicalB-Cell Maturation AntigenGPRC5D protein, humanReceptors, Chimeric AntigenReceptors, G-Protein-CoupledRNA, MessengerSingle-Chain AntibodiesTNFRSF17 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05849610ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.